Crisaborole is a nonsteroidal topical phosphodiesterase-4 (PDE4) inhibitor indicated for the treatment of mild-to-moderate atopic dermatitis in patients two years of age and older. The compounds within… Read more











Crisaborole is a nonsteroidal topical phosphodiesterase-4 (PDE4) inhibitor indicated for the treatment of mild-to-moderate atopic dermatitis in patients two years of age and older. The compounds within this category, including reference standards, synthetic impurities, metabolites, and stable isotope labelled analogues, are essential for rigorous pharmaceutical analysis and quality control. Laboratories utilize these high-quality materials for comprehensive impurity profiling, forced degradation studies, and method validation to ensure the efficacy and safety of the therapeutic agent. By serving as precise comparison benchmarks, these related compounds facilitate the accurate identification and quantification of impurities in drug substances and products, supporting reliable results in analytical techniques such as chromatography and mass spectrometry. These resources are fundamental to maintaining compliance with regulatory standards throughout the development and manufacturing lifecycle of the medication.